Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE.

Blood. 2007 Feb 15;109(4):1387-94. Epub 2006 Nov 2.

2.

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA.

Oncogene. 2005 Oct 20;24(46):6861-9.

PMID:
16007148
4.

A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.

Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Erlichman C, Peethambaram P, Pitot HC, Hanson LJ, Reid JM, Furth A, Cheng S, Martell RE, Kaufmann SH, Adjei AA.

Clin Cancer Res. 2005 Mar 1;11(5):1877-83.

5.

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.

Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM.

Blood. 2004 May 1;103(9):3271-7. Epub 2004 Jan 15.

PMID:
14726402
6.

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.

Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM, Narayanan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Sausville EA, Kaufmann SH.

Blood. 2003 Dec 15;102(13):4512-9. Epub 2003 Aug 14.

PMID:
12920036
7.

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH.

Clin Cancer Res. 2003 Jul;9(7):2520-6.

8.

Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH.

Clin Cancer Res. 2001 May;7(5):1438-45.

Supplemental Content

Loading ...
Support Center